Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Norman, OK 73069, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Immuno Mycologies Inc., a small business specializing in fungal disease diagnostics based in Norman, Oklahoma, was awarded a $210,000 Phase I Small Business Innovation Research (SBIR) contract by the National Institute of Allergy and Infectious Diseases on September 25, 2020. The firm-fixed-price contract, set aside for total small business participation, funds the development of an easy-to-use diagnostic test capable of early, rapid detection of Talaromyces antigen in human serum, plasma, and urine. The contract had a completion date of September 24, 2021 and stemmed from a solicitation posted in June 2019 seeking Phase I and II SBIR proposals to support National Institutes of Health and Centers for Disease Control and Prevention research priorities across multiple therapeutic and diagnostic areas.
This award represents a continuation of the National Institute of Allergy and Infectious Diseases' investment in Immuno Mycologies Inc.'s mycological diagnostic capabilities. The company has demonstrated expertise in this domain through its previous Phase II SBIR award valued at approximately $1.5 million for developing an enzyme immunoassay for detecting Talaromyces marneffei antigen, and through its established partnerships with the Department of Veterans Affairs and National Institutes of Health on various fungal disease diagnostic products. The Phase I contract provided initial funding to validate the rapid diagnostic test concept, positioning the contractor for potential Phase II expansion and commercialization of this innovative diagnostic solution.